Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 308(1): 49-52, 1996 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-8836631

RESUMO

Morphine is known to release histamine from mast cells and increase the turnover of neuronal histamine. It is also known that histamine receptors mediate some of the morphine effects. The contribution of histamine H1 and H2 receptors to the thermoregulatory effect of morphine in mice was investigated in the present experiments. Morphine produced a hypothermic effect, especially at the dose of 10 mg/kg. Although the histamine H1 receptor antagonist, dimethindene (0.1 mg/kg, i.p.), attenuated the hypothermic effect of morphine (10 mg/kg), a histamine H2 receptor antagonist, ranitidine (100 mg/kg, i.p.), had no effect. These results suggest that the hypothermic effect of morphine in mice is mediated, at least partly, through histamine H1 receptors.


Assuntos
Regulação da Temperatura Corporal , Morfina/farmacologia , Receptores Histamínicos H1/fisiologia , Animais , Temperatura Corporal/efeitos dos fármacos , Colo/fisiologia , Dimetideno/farmacologia , Antagonistas dos Receptores Histamínicos H1/farmacologia , Antagonistas dos Receptores H2 da Histamina/farmacologia , Masculino , Camundongos , Ranitidina/farmacologia
2.
Pharmacol Biochem Behav ; 52(4): 723-30, 1995 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8587911

RESUMO

In this study, we investigated the behavioral effects of MK-801 (1-20 micrograms) injected into the posterior parts of nucleus accumbens (ACC) and caudate-putamen (CP) in rats. Interactions of diazepam (DZP, 10 micrograms), haloperidol (HPD, 2 micrograms), and scopolamine (SCOP, 10 micrograms) with 20 micrograms of MK-801 were also studied. All injections were done in 2 microliters. In ACC, MK-801 increased locomotion, rearing, and head shakes. The effect of MK-801 especially at 20 micrograms was accompanied by a motor syndrome: head weaves, circling, body rolls, and ataxia. DZP nonsignificantly reduced the locomotion but it significantly (p < 0.05) reduced head shakes, weaves, circling, and body rolls produced by MK-801. HPD reduced grooming and head shakes. SCOP potentiated MK-801 hyperlocomotion, whereas it decreased body rolls, head shakes, and weaves. In CP, MK-801 increased locomotion, but less than in ACC (p < 0.05). The effect of MK-801 was significantly increased by SCOP. MK-801 also increased grooming (reduced by HPD and increased by SCOP) and at 5-20 micrograms induced oral movements that were decreased by HPD. These results indicate that the posterior part of ACC is involved in MK-801 hyperlocomotion and motor syndromes, whereas CP is involved in mediating grooming and oral movements. Blockade of the muscarinic cholinergic receptors seems to facilitate hyperlocomotion and decrease head shakes produced by MK-801. Mechanisms influenced by DZP and HPD appear to be involved in motor syndrome and oral movement, respectively, induced by MK-801, but not in hyperlocomotion.


Assuntos
Comportamento Animal/efeitos dos fármacos , Núcleo Caudado/efeitos dos fármacos , Maleato de Dizocilpina/farmacologia , Núcleo Accumbens/efeitos dos fármacos , Putamen/efeitos dos fármacos , Análise de Variância , Animais , Relação Dose-Resposta a Droga , Masculino , Ratos , Ratos Wistar , Fatores de Tempo
3.
Pharmacol Biochem Behav ; 51(2-3): 245-7, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7667335

RESUMO

The protective effect of moclobemide, a reversible and highly selective inhibitor of monoamine oxidase-A, against hypoxia-induced lethality was investigated in the present experiment. Moclobemide showed an apparent protective potency against hypoxia and significantly prolonged the latencies for convulsions and death in a dose-dependent manner. Hypothermia is known to protect animals from hypoxia. Moclobemide also decreased body temperature in mice; however, the hypothermic effect was unrelated to the antihypoxic effect. These results suggest that the protective effect of moclobemide in hypoxia is not due to a decrease in body temperature.


Assuntos
Anticonvulsivantes/uso terapêutico , Benzamidas/uso terapêutico , Temperatura Corporal/efeitos dos fármacos , Hipóxia/tratamento farmacológico , Animais , Relação Dose-Resposta a Droga , Hipóxia/fisiopatologia , Masculino , Camundongos , Moclobemida , Convulsões/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...